Fulcrum Therapeutics, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Fulcrum Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -3.28, a change of 1.8 year-over-year.
- Fulcrum Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -6.72.
- Fulcrum Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -10.04.
- Fulcrum Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -7.01.
- Fulcrum Therapeutics, Inc. pe ratio for fiscal 2026 was -3.28.
- Fulcrum Therapeutics, Inc. pe ratio for fiscal 2025 was -10.04.
- Available history
- 2025-06-30 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |